187 related articles for article (PubMed ID: 27192950)
41. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
[TBL] [Abstract][Full Text] [Related]
42. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
43. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
[TBL] [Abstract][Full Text] [Related]
44. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.
Harris JE; Harris TH; Weninger W; Wherry EJ; Hunter CA; Turka LA
J Invest Dermatol; 2012 Jul; 132(7):1869-76. PubMed ID: 22297636
[TBL] [Abstract][Full Text] [Related]
45. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
46. Tumour immunology: Intestinal bacteria are in command.
Alderton GK
Nat Rev Immunol; 2016 Jan; 16(1):5. PubMed ID: 26655627
[No Abstract] [Full Text] [Related]
47. Vitiligo: An Update on Pathophysiology and Treatment Options.
Speeckaert R; van Geel N
Am J Clin Dermatol; 2017 Dec; 18(6):733-744. PubMed ID: 28577207
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
49. Modularly Designed Peptide Nanoprodrug Augments Antitumor Immunity of PD-L1 Checkpoint Blockade by Targeting Indoleamine 2,3-Dioxygenase.
Han X; Cheng K; Xu Y; Wang Y; Min H; Zhang Y; Zhao X; Zhao R; Anderson GJ; Ren L; Nie G; Li Y
J Am Chem Soc; 2020 Feb; 142(5):2490-2496. PubMed ID: 31944687
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
51. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy of melanoma.
Kee D; McArthur G
Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic implications of autoimmune vitiligo T cells.
Oyarbide-Valencia K; van den Boorn JG; Denman CJ; Li M; Carlson JM; Hernandez C; Nishimura MI; Das PK; Luiten RM; Le Poole IC
Autoimmun Rev; 2006 Aug; 5(7):486-92. PubMed ID: 16920575
[TBL] [Abstract][Full Text] [Related]
54. The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis.
Legány N; Berta L; Kovács L; Balog A; Toldi G
Immunol Res; 2017 Jun; 65(3):622-629. PubMed ID: 27878564
[TBL] [Abstract][Full Text] [Related]
55. Update on immunotherapy in melanoma.
Green J; Ariyan C
Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
[TBL] [Abstract][Full Text] [Related]
56. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
57. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
58. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
59. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.
Ye Y; Wang J; Hu Q; Hochu GM; Xin H; Wang C; Gu Z
ACS Nano; 2016 Sep; 10(9):8956-63. PubMed ID: 27599066
[TBL] [Abstract][Full Text] [Related]
60. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
